Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 1/20 | 0.40 |
| ▸ | MLNR | O43193 | 2/20 | 0.38 |
| ▸ | HPGDS | O60760 | 2/20 | 0.37 |
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.36 |
| ▸ | WNT3A | P56704 | 6/20 | 0.35 |
| ▸ | MMP1 | P03956 | 3/20 | 0.34 |
| ▸ | MMP3 | P08254 | 3/20 | 0.34 |
| ▸ | MMP7 | P09237 | 3/20 | 0.34 |
| ▸ | MMP9 | P14780 | 3/20 | 0.34 |
| ▸ | MMP13 | P45452 | 3/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL328559 | 0.82 | MMP1 (0.50) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL14878483 | 0.74 | F2R (0.41) | F2RMLNRHPGDSP2RY12MMP1 | |
| SCHEMBL779217 | 0.74 | MMP1 (0.51) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL12905511 | 0.73 | F2R (0.41) | F2RMLNRHPGDSP2RY12MMP1 | |
| SCHEMBL16507789 | 0.73 | MMP9 (0.39) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL15596869 | 0.72 | MMP1 (0.37) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL31389056 | 0.70 | MLNR (0.38) | F2RMLNRHPGDSWNT3AMMP1 | |
| SCHEMBL31653848 | 0.69 | MMP3 (0.36) | MLNRHPGDSMMP1MMP3MMP7 | |
| SCHEMBL14959637 | 0.68 | KMT2A (0.36) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL2070138 | 0.66 | HPGDS (0.64) | HPGDSMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1511488-B1 | HUMAN ADAM-10 INHIBITORS | SYMPHONY EVOLUTION INC (US) | 2013-05-22 | — | — | EP | disclosed |
| WO-2011041545-A1 | METHODS OF TREATING ANEURYSMAL DILATATION, BLOOD VESSEL WALL WEAKNESS AND SPECIFICALLY ABDOMINAL AORTIC AND THORACIC ANEURYSM USING MATRIX METALLOPROTEASE-2 INHIBITORS | SYMPHONY EVOLUTION, INC. (US) | 2011-04-07 | — | — | WO | disclosed |